오가노이드 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global organoids market size is expected to reach USD 7.68 Billion in 2034 from USD 1.67 Billion in 2025, growing at a CAGR of 18.47% during 2026-2034.This market is expanding as researchers increasingly use three-dimensional organoid models to study human biology, disease mechanisms, drug responses, and developmental processes. Organoids are laboratory-grown structures that can reproduce selected characteristics of organs or tissues. Their ability to provide more biologically representative models than some conventional two-dimensional cell cultures is encouraging adoption in pharmaceutical research and academic laboratories. Increasing investment in precision medicine and advanced biological modeling is also supporting demand for organoid technologies and associated culture systems.

Pharmaceutical companies are exploring organoids for drug screening, toxicity assessment, disease modeling, and biomarker research. Researchers can develop organoids representing tissues such as the intestine, brain, liver, kidney, and other biological systems, depending on the technology. Patient-derived organoids are particularly relevant to personalized research because they can help investigators study individual biological responses. Improvements in culture media, scaffolds, imaging, automation, and analytical tools are making organoid workflows increasingly sophisticated and reproducible.

Future prospects are supported by the growing need for human-relevant research models and more efficient drug-development processes. Automation and high-throughput screening could increase the practical use of organoids in pharmaceutical research. Integration with artificial intelligence and advanced imaging may enable more detailed analysis of organoid behavior and drug responses. Standardization remains an important requirement because variability between laboratories and models can affect reproducibility. Continued advances in stem-cell biology, tissue engineering, and analytical technologies are expected to broaden organoid applications.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Source

• Pluripotent Stem-Cell-Derived Organoids
• Adult Stem-Cell-Derived Organoids
• Tumor-Derived Patient Organoids

By Organ Type

• Intestinal
• Liver
• Brain
• Kidney
• Lung
• Pancreas
• Cardiac
• Other Organ Types

By Application

• Drug Discovery & Screening
• Disease & Toxicology Modelling
• Precision & Personalised Medicine
• Regenerative Medicine
• Organoid Biobanking Services
• Other Applications

By End User

• Academic & Research Institutes
• CROs & CDMOs
• Hospitals & Diagnostics Labs
• Pharmaceutical & Biotech Companies

By Technology

• 3-D Bioprinting-Assisted Organoids
• AI-Guided Automated Platforms
• Micro-Fluidic Organ-On-Chip Integrated
• Scaffold-Based 3-D Culture
• Suspension / Scaffold-Free Culture

COMPANIES PROFILED

• Advanced BioMatrix Inc., ATCC, BICO Group AB, Cellesce Ltd, CN Bio Innovations Ltd, Corning Inc., Emulate Inc., Eppendorf SE, Greiner Bio-One International GmbH, HeartBeat.bio AG, Hubrecht Organoid Technology, InSphero AG, Lonza Group AG, Merck KGaA, MIMETAS BV, Miltenyi Biotec B.V. & Co. KG, QGel SA, Sartorius AG, STEMCELL Technologies Inc., Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ORGANOIDS MARKET: BY SOURCE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Source
• 4.2. Pluripotent Stem-Cell-Derived Organoids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Adult Stem-Cell-Derived Organoids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Tumor-Derived Patient Organoids Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ORGANOIDS MARKET: BY ORGAN TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Organ Type
• 5.2. Intestinal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Liver Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Brain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Kidney Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Lung Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Pancreas Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Cardiac Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Other Organ Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ORGANOIDS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Drug Discovery & Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Disease & Toxicology Modelling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Precision & Personalised Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Regenerative Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Organoid Biobanking Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ORGANOIDS MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. CROs & CDMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Hospitals & Diagnostics Labs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Pharmaceutical & Biotech Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ORGANOIDS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Technology
• 8.2. 3-D Bioprinting-Assisted Organoids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. AI-Guided Automated Platforms Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Micro-Fluidic Organ-On-Chip Integrated Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Scaffold-Based 3-D Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.6. Suspension / Scaffold-Free Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ORGANOIDS MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Source
  • 9.2.2 By Organ Type
  • 9.2.3 By Application
  • 9.2.4 By End User
  • 9.2.5 By Technology
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Source
  • 9.3.2 By Organ Type
  • 9.3.3 By Application
  • 9.3.4 By End User
  • 9.3.5 By Technology
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Spain
  • 9.3.11 Russia
  • 9.3.12 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Source
  • 9.4.2 By Organ Type
  • 9.4.3 By Application
  • 9.4.4 By End User
  • 9.4.5 By Technology
  • 9.4.6 China
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 India
  • 9.4.10 Australia
  • 9.4.11 South East Asia
  • 9.4.12 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Source
  • 9.5.2 By Organ Type
  • 9.5.3 By Application
  • 9.5.4 By End User
  • 9.5.5 By Technology
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Source
  • 9.6.2 By Organ Type
  • 9.6.3 By Application
  • 9.6.4 By End User
  • 9.6.5 By Technology
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ORGANOIDS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Advanced BioMatrix Inc
  • 11.2.2 ATCC
  • 11.2.3 BICO Group AB
  • 11.2.4 Cellesce Ltd
  • 11.2.5 CN Bio Innovations Ltd
  • 11.2.6 Corning Inc
  • 11.2.7 Emulate Inc
  • 11.2.8 Eppendorf SE
  • 11.2.9 Greiner Bio-One International GmbH
  • 11.2.10 HeartBeat.bio AG
  • 11.2.11 Hubrecht Organoid Technology
  • 11.2.12 InSphero AG
  • 11.2.13 Lonza Group AG
  • 11.2.14 Merck KGaA
  • 11.2.15 MIMETAS BV
  • 11.2.16 Miltenyi Biotec B.V. & Co. KG
  • 11.2.17 QGel SA
  • 11.2.18 Sartorius AG
  • 11.2.19 STEMCELL Technologies Inc
  • 11.2.20 Thermo Fisher Scientific Inc